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Abstract 
 
Objective: The smoking rate among patients with mental health 
problem is higher than in the general population. Effective 
pharmacotherapy to treat nicotine addiction is thus needed to reduce 
the morbidity and mortality associated with cigarette smoking among 
these patients. This article reviews the literature on the suitability of 
varenicline for smokers with mental health problems. Methods: A 
search of the literature was conducted using PubMed from year 2001 
to July 2009 using key words varenicline alone and varenicline and 
mental health. Articles chosen were narrowed to those published in 
English. The type of articles chosen included clinical trials, meta-
analyses, case reports, and review articles. Results: The search 
produced a total of 322 articles on varenicline and 14 articles on 
varenicline and mental health. Varenicline, a new drug for smoking 
cessation is an α4β2 partial agonist and partial antagonist at nicotinic 
acetylcholine receptor. As a partial agonist, varenicline relieves 
craving and withdrawal symptoms that occur during smoking 
abstinence and also reduce the rewarding effects of smoking in 
patients who relapse. However, at present, there is concern regarding 
the neuropsychiatric side effects such as aggressive behaviour, 
suicidal ideation, mania and depression associated with varenicline 
use in patients with mental health problems, but these reports did not 
show a causal-link or lack of link between these symptoms and 
varenicline. Conclusion: Current available data support the 
effectiveness of varenicline to treat nicotine dependence. However its 
safety among smokers with mental health problems remains to be 
elucidated. At present, further safety assessment is needed in this 
patient population. Until new data is available regarding the safety of 
varenicline in these populations, psychiatrists and physicians 
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prescribing this medication should be extra cautious and monitor for 
possible psychiatric side effects when prescribing this medication to 
patients with pre-existing psychiatric disorders or have vulnerability 
to psychoses. ASEAN Journal of Psychiatry, Vol. 10(2): July- Dec 2009: 
XX XX 
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Introduction 
 
Cigarette smoking is the single most 
preventable cause of death in the world. 
Smoking is responsible for 
cardiovascular and respiratory diseases, 
cerebrovascular diseases and cancer. It is 
well known that the smoking prevalence 
among mental health patients is higher 
than the general population. For instance, 
smoking rate among schizophrenia 
patients is reported to be between two to 
four times higher than the general 
population. Smokers with schizophrenia 
also smoke more cigarettes per day and 
smoke stronger brands than other 
smokers [1].  
 
Many smokers with schizophrenia report 
that smoking helps to reduce their 
symptoms [2]. This has been confirmed 
by studies showing that smoking is 
related to a reduction in the negative 
symptoms of schizophrenia, such as lack 
of motivation and social withdrawal. 
Smokers with schizophrenia also report 
that smoking increases their alertness, 
enhance concentration, thinking and 
learning. This is beneficial to 
schizophrenics whose illness or 
medication leads to cognitive problems. 
Patients with mental problems also 
report that smoking help them relax and 
reduce negative feelings such as anxiety, 
tension and anger, thus helping them 
deal with stressful situations [1]. It is 
thought that these effects are caused by 
nicotine’s ability to raise dopamine 
levels in areas of the brain involved in 
attention and engaging with one’s 
surroundings [2]. Patients with mental 
health problems also report that smoking 
help to relieve boredom and improve 
social interaction, something which is of 
benefit in those with negative symptoms.  
 
Given the negative effects of smoking on 
health, including greatly increased risk 
of heart disease and cancer, there is thus 
an urgent need for effective 
pharmacotherapy to treat smokers with 
mental health problems.  
 
Why quit? 
 
The benefits of stopping smoking had 
been well demonstrated. Smoking 
cessation provides both short-term and 
long-term health benefits and has been 
shown to reduce both morbidity and 
mortality related to nicotine addiction 
[3]. Stopping smoking improves health 
outcomes and could reverse disease 
progression. At 3 months of cessation, 
lung function may start to improve with 
decrease cough, sinus congestion, 
fatigue and shortness of breath [4]. At 1 
year, risk of coronary heart disease is 
reduced by 50% among ex-smokers and 
by 5 years the risk of stroke returns to 
the level of people who have never 
smoked. By 10 years, the risk of lung 
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 cancer reduces to 30-50% of those who 
continue to smoke and by 15 years 
cardiovascular heart disease becomes 
similar to never smokers [3-5]. 
 
Smoking cessation at any age also 
increases life expectancy [4]. It has been 
reported that stopping smoking at 50 
years old reduces the risk of death from 
smoking related causes by half. The 
effect is better if quitting at an early age, 
where stopping smoking at age 30 had 
been shown to avoid smoking related 
mortality. It was also shown that the 
benefits of stopping smoking was 
observed regardless of age when 
stopping smoking, but stopping sooner 
appeared to be the most beneficial. In 
general in those who continue to smoke, 
smoking reduces survival an average of 
10 years [6]. 
 
Methods  
 
A search of the literature was conducted 
using PubMed from year 2001 to July 
2009 using key words varenicline alone 
and varenicline and mental health.  
 
Results 
 
The search produced a total of 322 
articles on varenicline and 14 articles on 
varenicline and mental health. Articles 
chosen were narrowed to those 
published in English and limited to 
studies done on human subjects. Case 
reports, meta-analyses, review articles 
and clinical trials evaluating the safety, 
efficacy and adverse effects of 
varenicline were included [7-25].  
 
 
 
 
 
Discussion 
 
Varenicline 
 
It is difficult to stop smoking and this is 
due to the highly addictive nature of 
nicotine. Nicotine is responsible for the 
physical and psychological rewards of 
smoking reinforcement. After inhalation, 
nicotine from cigarettes reach the brain 
in less than 10 seconds and binds 
predominantly to the α4β2 subtype of 
the nicotinic receptor in the brain. 
Recent evidence supports the role of 
α4β2 nicotinic acetylcholine receptor in 
the reinforcing effects of nicotine use 
[18].  Varenicline is a α4β2 partial 
agonist, a compound with dual agonist 
and antagonist activities. This is believed 
to result in lesser amount of dopamine 
release from the ventral tegmental area 
at the nucleus accumbens (32-45%) as 
well as the prevention of nicotine 
binding at the α4β2 receptors, thus 
preventing a pharmacologic reward 
during relapse. When used as part of a 
programme that includes advice from a 
healthcare professional, varenicline has 
been shown to relieve nicotine craving 
and withdrawal symptoms while 
reducing the reinforcing effects of 
nicotine [8]. Varenicline is indicated as 
an option for smokers who have 
expressed a desire to stop smoking, and 
should be prescribed only as part of a 
programme of behavioural support. It is 
also emphasized that smoking cessation 
treatments were more successful in 
patients who were provided with 
additional advice and support.  
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The efficacy of varenicline in treating 
tobacco dependence is believed to result 
from partial agonist activity at the α4β2 
nicotinic receptor. By preventing 
binding of nicotine, varenicline reduces 
craving and withdrawal symptoms 
(agonist activity) and produces a 
reduction of the rewarding and 
reinforcing effects of smoking 
(antagonist activity) by preventing 
nicotine binding to α4β2 receptors. A 
study on both male and female smokers 
in an outpatient setting reported that 
44% of smokers treated with varenicline 
were abstinent at 12 weeks compared to 
placebo (17.7%) [19].  
 
The most common adverse event 
associated with varenicline treatment 
was nausea but this was described as 
mild or moderate and was generally at 
the start of therapy and decreased over 
time. Other reported adverse events were 
abnormal dreams, insomnia and 
headache. Rare side effects reported 
were change in taste, vomiting, 
abdominal pain, flatulence and 
constipation. However, the reported 
discontinuation of treatment from 
varenicline was 7-14% [19].  
 
Suitability for use in patients with 
mental health problems 
 
The efficacy and safety of varenicline in 
Asian smokers has been established in 
randomised double-blind, placebo 
controlled trials among smokers in 
Taiwan, Japan, Korea, China, Thailand 
and Singapore [14-16]. However, the 
literature has reported contradictory 
reports regarding the safety and efficacy 
of varenicline in psychiatric patients [8, 
20-25]. Some reports regarding 
varenicline have been favourable. A 
recent study found varenicline to be safe 
for patients with mental health problems 
and was superior in maintaining 
smoking abstinence. The study was a 
non-randomised study of 412 smokers in 
a community clinic which included 111 
patients with mental health problems 
[the primary diagnosis were depression 
(64), bipolar disorder (14), psychosis (7), 
psychosis and depression (24) and 
bipolar disorder (2)]. However the small 
sample size and varying psychiatric 
diagnosis precluded any firm conclusion 
[8]. A preliminary investigation also 
demonstrated that varenicline 
significantly reduced alcohol self-
administration and was well tolerated, 
either varenicline alone and in 
combination with alcohol in heavy-
drinking smokers and suggested that 
varenicline should be investigated as a 
potential treatment for alcohol use 
disorders [23]. However the literature 
has also reported several cases including 
suicidal ideation and occasional suicidal 
behaviour, erratic behaviour and 
drowsiness [24]. There was also a single 
case of an activated psychotic relapse in 
a schizophrenic patient receiving 
varenicline [20]. Another report 
described a hypomania with agitation 
episode associated with varenicline use 
in bipolar II disorder and another case 
report described an induction of a manic 
episode in a bipolar patient [25]. 
Another published case was regarding a 
person who shot his neighbour after 
being a state of delirium caused by 
taking varenicline with a high dose of 
alcohol. It was also unclear whether the 
episode was related to the drug or a state 
of alcohol intoxication. Other post-
marketing reports included agitation and 
depression [26].  As for inpatient setting, 
a recent article reported worsening of 
psychosis and agitation in a patient who 
was treated for nicotine cravings, but 
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 returned of mental status to baseline 
upon discontinuation of varenicline [24]. 
Most recently, acute hepatic injury with 
raised liver enzymes were reported in an 
alcoholic patient. The enzyme alkaline 
phosphatase level was reported to reduce 
to normal within one month of 
discontinuation of varenicline and the 
enzyme aminotransferase level was 
shown to reduce to normal after four 
months of discontinuation of the drug. In 
all the cases reported above, a causal 
connection or lack of connection 
between varenicline and these symptoms 
were not established [24]. However, 
varenicline is reported to cause 
dysregulation of the dopaminergic 
system, and this may lead to 
exacerbation of psychotic symptoms in 
patients with psychotic disease. 
Varenicline has also been linked to 
neuronal α7 nAChR1, which is linked to 
major psychiatric disorders [20, 25]. 
 
At present, whether the neuropsychiatric 
symptoms reported is causal, 
coincidental or a result of varenicline 
remains to be elucidated [17]. In all the 
examples stated in the paragraph above, 
it was not clear whether the psychiatric 
symptoms were related to the drug or 
nicotine withdrawal symptoms. As a 
result of these reports, the US FDA has 
now issued an order for the manufacturer 
of this drug to highlight these effects on 
the product box [25].  
 
On the other hand, the Diagnostic and 
Statistical Manual of Mental Disorders, 
4
th
 Edition- Text Revision acknowledged 
that some of the psychological 
symptoms from nicotine withdrawal 
include dysphoric and depressed mood, 
insomnia, irritability, frustration or anger, 
anxiety, difficulty concentrating and 
restlessness. Thus, when prescribing 
varenicline to mental health patients, it is 
prudent to consider the beneficial effect 
of varenicline in achieving and 
maintaining abstinence in millions of 
smokers compared to the reported 
adverse events.  
 
Prior to starting varenicline, it is thus 
important to enquire regarding mental 
illness in smokers. Until new data 
pertaining to the safety of varenicline in 
mental health patients become available, 
based on current information and 
knowledge from the literature, it is 
recommended that: (1) Patients with 
mental problems should be given advice 
and alerted to the risk of varenicline on 
their existing illness. Extra caution is 
needed in patients with psychiatric 
illness such as schizophrenia, bipolar 
disorder and major depressive illness 
who may experience worsening of their 
pre-existing illness when prescribed 
varenicline. For smokers with mental 
health problems who have been 
prescribed varenicline, advice should be 
given to their families and carers to be 
alert to changes in mood and behaviour. 
If such changes do occur, it is important 
to seek immediate medical assistance. 
(2) Alternative pharmacotherapy should 
be considered for smokers with mental 
health problems who wish to stop 
smoking as thus far there is insufficient 
data to certify the safety of varenicline 
for smokers with mental health problems. 
However, psychiatrists and health 
personnel who do decide to prescribe 
varenicline should monitor their patients 
for serious neuropsychiatric symptoms 
such as changes in behaviour, agitation, 
depressed mood, suicidal ideas and 
suicidal behaviour. If in doubt, another 
smoking cessation pharmacotherapy 
should be considered. (5) Patients with 
serious mental health problems should 
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be offered other type of pharmacological 
treatment, e.g. nicotine replacement 
therapy.  
 
Conclusion 
 
The prevalence of smoking among 
mental health patients is higher than the 
general population. Cigarette smoking 
on the other hand is an important cause 
of morbidity and mortality. Thus, 
effective smoking cessation treatment is 
needed to curb these health problems 
among mental health patients. 
Varenicline is a new class of drug for 
smoking cessation. It is a selective 
partial nicotinic receptor agonist which 
reduce craving and blocks the reward 
from smoking and offers a new 
pharmacotherapy option for smoking 
cessation. Thus far, more information is 
needed regarding the safety of 
varenicline in smokers with mental 
health problems. Hence caution is 
needed when prescribing varenicline to 
patients known to have mental health 
problems. Further research is needed to 
establish the safety profile of varenicline 
in these patients. 
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